Purpose: The aim of this study was to prepare wheat germ agglutinin (WGA)-modified liposomes encapsulating clarithromycin and to evaluate their in vitro and in vivo efficacy against Methicillin-resistant Staphylococcus aureus (MRSA).

Methods: Physicochemical parameters, minimum inhibitory concentrations, in vitro killing kinetic, cellular uptake, biofilm formation inhibition and pre-formed biofilm destruction, biodistribution, in vivo antibacterial efficacy against MRSA, and phagocytosis into macrophages for liposomes loading clarithromycin were determined.

Results: The minimum inhibitory concentration and the time-kill curve for WGA-modified liposomal clarithromycin were better than those of free and nonmodified liposomal clarithromycin. Flow cytometry analysis displayed that liposomes could deliver more Coumarin 6, a fluorescent probe, into bacteria because of the conjugation of WGA. Besides, WGA-modified liposomal clarithromycin inhibited formation of S. aureus (ATCC 29213) and MRSA biofiom, and prompted the biofilm disassembly at lower concentrations below MIC. Effective accumulation of liposomes was displayed in the enterocoelia of the mice because of WGA. The number of MRSA colony-forming units in the kidney and spleen in mice treated with WGA-modified liposomal clarithromycin was significantly lower than that treated with free and nonmodified clarithromycin (p < 0.05). Intracellular localization of MRSA occurred in a significantly higher proportion of macrophage exposed to WGA-modified liposomes compared to those exposed to nonmodified liposomes.

Conclusions: Liposome modified by WGA is a promising formulation for bacteria targeted delivery and immunity defensive system through macrophage improving uptake of bacteria, biodistribution, in vitro and in vivo antibacterial efficacy against MRSA.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-015-1825-9DOI Listing

Publication Analysis

Top Keywords

liposomal clarithromycin
16
wga-modified liposomal
12
methicillin-resistant staphylococcus
8
staphylococcus aureus
8
minimum inhibitory
8
free nonmodified
8
clarithromycin
7
multi-functional liposomes
4
liposomes enhancing
4
enhancing target
4

Similar Publications

A 55-year-old man presented to our hospital with idiopathic pulmonary fibrosis (IPF). He was registered with the Japan Organ Transplant Network the following year due to disease progression. Treatment with clarithromycin, ethambutol, and rifampicin for complications of Mycobacterium avium pulmonary disease was initiated, but sputum conversion could not be achieved.

View Article and Find Full Text PDF
Article Synopsis
  • Amikacin liposome inhalation suspension (ALIS) showed effectiveness in increasing sputum culture conversion rates in patients with refractory Mycobacterium avium complex pulmonary disease (MAC-PD) after 6 months of treatment in a phase 3 trial.
  • A study involving 12 patients at Toho University revealed that 58.3% achieved culture conversion, with factors like shorter previous treatment duration and fewer cavitary lesions on chest CT linked to better outcomes.
  • While improvements in chest CT findings were noted, they did not always match with culture conversion results, indicating that the correlation between imaging and treatment success is complex.
View Article and Find Full Text PDF

The increasing prevalence of complex (MAC) pulmonary disease poses a significant therapeutic challenge, particularly due to the limited efficacy and systemic toxicity associated with conventional guideline-based therapy. Amikacin liposome inhalation suspension (ALIS) has been developed, yet its real-world application remains underreported. This retrospective analysis, conducted from March 2021 to February 2024, examined ALIS's clinical use in patients aged 20 years or older with refractory MAC pulmonary disease at our institution.

View Article and Find Full Text PDF

An all-in-one therapeutic platform for the treatment of resistant Helicobacter pylori infection.

Biomaterials

July 2024

Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China. Electronic address:

Helicobacter pylori (H. pylori) infection is a major cause of gastric diseases. Currently, bismuth-based quadruple therapy is widely adopted for eradicating H.

View Article and Find Full Text PDF

This study aimed to investigate the effects of topical liposomal clarithromycin in combination with (Glucantime) on cutaneous leishmaniasis (CL) lesions. This pilot, randomized, double-blinded clinical trial was conducted on patients with CL lesions. Patients were randomly assigned to two groups: the first group received liposomal clarithromycin in combination with Glucantime for 28 days, while the second group received Glucantime and a placebo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!